Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.

MLA

Capeding, Maria Rosario, et al. “Immunogenicity, Safety and Reactogenicity of a Phase II Trial of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Infants and Toddlers: A Preliminary Report.” Vaccine, vol. 38, no. 28, June 2020, pp. 4476–83. EBSCOhost, https://doi.org/10.1016/j.vaccine.2019.09.074.

APA

Capeding, M. R., Alberto, E., Sil, A., Saluja, T., Teshome, S., Kim, D. R., Park, J. Y., Yang, J. S., Chinaworapong, S., Park, J., Jo, S.-K., Chon, Y., Yang, S.-Y., Ham, D. S., Ryu, J. H., Lynch, J., Kim, J. H., Kim, H., Excler, J.-L., … Sahastrabuddhe, S. (2020). Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report. Vaccine, 38(28), 4476–4483. https://doi.org/10.1016/j.vaccine.2019.09.074

Chicago

Capeding, Maria Rosario, Edison Alberto, Arijit Sil, Tarun Saluja, Samuel Teshome, Deok Ryun Kim, Ju Yeon Park, et al. 2020. “Immunogenicity, Safety and Reactogenicity of a Phase II Trial of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Infants and Toddlers: A Preliminary Report.” Vaccine 38 (28): 4476–83. doi:10.1016/j.vaccine.2019.09.074.